このページの翻訳は実験的なもので、現在開発中です。お待ちしております！

Gentian Diagnostics 将来の成長

Future 基準チェック /56

Gentian Diagnosticsは、11.7%と20.9%でそれぞれ年率11.7%で利益と収益が成長すると予測される一方、EPSはgrowで119.6%年率。

主要情報

11.7%

収益成長率

119.6%

EPS成長率

Medical Equipment 収益成長	18.3%
収益成長率	20.9%
将来の株主資本利益率	n/a
アナリストカバレッジ	Low
最終更新日	27 May 2024

今後の成長に関する最新情報

Analyst Estimates: Here's What Brokers Think Of Gentian Diagnostics ASA (OB:GENT) After Its Annual Report

Feb 14

Recent updates

Analyst Estimates: Here's What Brokers Think Of Gentian Diagnostics ASA (OB:GENT) After Its Annual Report

Feb 14

Here's Why We're Not At All Concerned With Gentian Diagnostics' (OB:GENT) Cash Burn Situation

Oct 28

We're Not Worried About Gentian Diagnostics' (OB:GENT) Cash Burn

May 11

Can You Imagine How Gentian Diagnostics' (OB:GENT) Shareholders Feel About The 57% Share Price Increase?

Mar 20

業績と収益の成長予測

OB:GENT - アナリストの将来予測と過去の財務データ ( )NOK Millions
日付	収益	収益	フリー・キャッシュフロー	営業活動によるキャッシュ	平均アナリスト数
12/31/2026	263	-4	N/A	N/A	1
12/31/2025	226	14	9	18	1
12/31/2024	174	8	-5	5	1
3/31/2024	149	-6	15	21	N/A
12/31/2023	142	-11	11	15	N/A
9/30/2023	132	-5	-12	-7	N/A
6/30/2023	124	-14	-6	0	N/A
3/31/2023	120	-18	-19	-6	N/A
12/31/2022	112	-24	-29	-14	N/A
9/30/2022	106	-29	-34	-19	N/A
6/30/2022	100	-26	-43	-26	N/A
3/31/2022	99	-26	-42	-29	N/A
12/31/2021	100	-25	-40	-27	N/A
9/30/2021	99	-19	-24	-9	N/A
6/30/2021	96	-19	-27	-16	N/A
3/31/2021	84	-17	-20	-12	N/A
12/31/2020	79	-17	-19	-13	N/A
9/30/2020	72	-21	-16	-13	N/A
6/30/2020	70	-19	-16	-13	N/A
3/31/2020	62	-38	-28	-25	N/A
12/31/2019	55	-40	-26	-21	N/A
9/30/2019	44	-46	-25	-20	N/A
6/30/2019	48	-41	-22	-17	N/A
3/31/2019	47	-23	-18	-12	N/A
12/31/2018	46	-20	-17	-11	N/A
9/30/2018	51	-12	-23	-18	N/A
6/30/2018	41	-16	-24	-19	N/A
3/31/2018	40	-14	-21	-16	N/A
12/31/2017	35	-15	N/A	-19	N/A
9/30/2017	34	-13	N/A	-19	N/A
6/30/2017	32	-12	N/A	-18	N/A
3/31/2017	30	-13	N/A	-16	N/A
12/31/2016	31	-9	N/A	-8	N/A
12/31/2015	26	-3	N/A	-5	N/A
12/31/2014	25	-3	N/A	-2	N/A
12/31/2013	23	1	N/A	2	N/A

アナリストによる今後の成長予測

収入対貯蓄率: GENTは今後 3 年間で収益性が向上すると予測されており、これは貯蓄率 ( 2.1% ) よりも高い成長率であると考えられます。

収益対市場: GENT今後 3 年間で収益性が向上すると予想されており、これは市場平均を上回る成長と考えられます。

高成長収益: GENT今後 3 年以内に収益を上げることが予想されます。

収益対市場: GENTの収益 ( 20.9% ) Norwegian市場 ( 1.3% ) よりも速いペースで成長すると予測されています。

高い収益成長: GENTの収益 ( 20.9% ) 20%よりも速いペースで成長すると予測されています。

一株当たり利益成長率予想

将来の株主資本利益率

将来のROE: GENTの自己資本利益率が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です

Gentian Diagnostics 将来の成長

Future 基準チェック /56

主要情報

今後の成長に関する最新情報

Analyst Estimates: Here's What Brokers Think Of Gentian Diagnostics ASA (OB:GENT) After Its Annual Report

Consensus estimates of losses per share improve by 70%

Consensus estimates of losses per share improve by 31%

Consensus EPS estimates fall by 12%

Price target decreased by 43% to kr52.00

Consensus forecasts updated

Recent updates

Now 20% undervalued after recent price drop

First quarter 2024 earnings released: EPS: kr0.27 (vs kr0.043 loss in 1Q 2023)

Gentian Diagnostics ASA Appoints Mr. Njaal Kind as Acting CEO

Full year 2023 earnings released: kr0.69 loss per share (vs kr1.53 loss in FY 2022)

Analyst Estimates: Here's What Brokers Think Of Gentian Diagnostics ASA (OB:GENT) After Its Annual Report

Full year 2023 earnings released: kr0.67 loss per share (vs kr1.53 loss in FY 2022)

Gentian Diagnostics Asa Announces Resignation of Frank Frantzen from the Board of Directors

Gentian Diagnostics ASA to Report Q4, 2023 Results on Feb 09, 2024

Consensus estimates of losses per share improve by 70%

New major risk - Revenue and earnings growth

Third quarter 2023 earnings released

CFO & COO recently bought kr217k worth of stock

First quarter 2023 earnings released

Consensus estimates of losses per share improve by 31%

Full year 2022 earnings: EPS exceeds analyst expectations

Gentian Diagnostics Asa Announces New Study Addresses the Use of Plasma Calprotectin in Sepsis Management

Consensus EPS estimates fall by 12%

Price target decreased by 43% to kr52.00

Gentian Diagnostics ASA Announces Executive Changes, Effective from 1 January 2023

Gentian Diagnostics ASA to Report Q4, 2022 Results on Feb 16, 2023

Gentian Diagnostics ASA, Annual General Meeting, May 04, 2023

Gentian Diagnostics ASA Receives Patent for NT-proBNP in the U.S

No independent directors

Consensus forecasts updated

Third quarter 2022 earnings: Revenues exceed analyst expectations

Here's Why We're Not At All Concerned With Gentian Diagnostics' (OB:GENT) Cash Burn Situation

Consensus forecasts updated

Director recently bought kr96k worth of stock

Second quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Gentian Diagnostics ASA Announces Executive Appointments

We're Not Worried About Gentian Diagnostics' (OB:GENT) Cash Burn

First quarter 2022 earnings: Revenues miss analyst expectations

No independent directors

Gentian Diagnostics Asa Announce the Release of the Novel Ce Marked Sars-Cov-2 Total Antibody Immunoassay

Director recently bought kr203k worth of stock

Consensus forecasts updated

Full year 2021 earnings: EPS exceeds analyst expectations while revenues lag behind

Gentian Diagnostics AS Completes Development of SARS Cov-2 Antibody Assay

Third quarter 2021 earnings released

Price target increased to kr104

Second quarter 2021 earnings released: kr0.23 loss per share (vs kr0.092 loss in 2Q 2020)

First quarter 2021 earnings released

Can You Imagine How Gentian Diagnostics' (OB:GENT) Shareholders Feel About The 57% Share Price Increase?

What Percentage Of Gentian Diagnostics AS (OB:GENT) Shares Do Insiders Own?

Gentian Diagnostics as Announces Publication of NT-ProBNP Patent Application

Full year 2020 earnings released: kr1.13 loss per share (vs kr2.59 loss in FY 2019)

Have Insiders Been Selling Gentian Diagnostics AS (OB:GENT) Shares?

New 90-day low: kr52.50

New 90-day low: kr56.00

Gentian Diagnostics AS (OB:GENT): When Will It Breakeven?

Gentian Diagnostics AS Announces New Study Results Confirm the Value of Calprotectin in Management of COVID-19 Patients

New 90-day low: kr60.50

Third quarter earnings released

Insider recently sold kr3.0m worth of stock

Earnings released

New 90-day high - kr64.00

業績と収益の成長予測

アナリストによる今後の成長予測

一株当たり利益成長率予想

将来の株主資本利益率

成長企業の発掘